Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TMC435 plus peginterferon/ribavirin in treatment-naive genotype 1 hepatitis C
2010-021174-11Phase 3Completed
- Sponsor
- Tibotec
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C virus infection comparing TMC435 + peginterferon/ribavirin with Placebo + peginterferon/ribavirin (2 arms). Primary endpoint: Sustained virologic response at week 60. Started Nov 2010; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-021174-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021174-11.